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Abstract
Chronic kidney disease is linked to systemic inflammation and to an increased risk of ischemic heart disease and
atherosclerosis. Endothelial dysfunction associates with hypertension and vascular disease in the presence of chronic kidney
disease but the mechanisms that regulate the activation of the endothelium at the early stages of the disease, before
systemic inflammation is established remain obscure. In the present study we investigated the effect of serum derived from
patients with chronic kidney disease either before or after hemodialysis on the activation of human endothelial cells in vitro,
as an attempt to define the overall effect of uremic toxins at the early stages of endothelial dysfunction. Our results argue
that uremic toxins alter the biological actions of endothelial cells and the remodelling of the extracellular matrix before
signs of systemic inflammatory responses are observed. This study further elucidates the early events of endothelial
dysfunction during toxic uremia conditions allowing more complete understanding of the molecular events as well as their
sequence during progressive renal failure.
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Introduction
Chronic kidney disease (CKD) is due to a progressive loss of
renal function that may lead to complications such as cardiovas-
cular disease or pericarditis. To fully investigate the underlying
cause of kidney damage, various forms of medical imaging, blood
tests or renal biopsy are employed to find out if there is a reversible
cause for the kidney malfunction. Established CKD or chronic
renal failure (CRF) are terms that describe the late stage of kidney
damage, when the disease is considered irreversible. Current
therapy strategies aim the delay of the clinical manifestations to the
final stages of the disease. Generally, agents targeting the
functional control of the endothelium, such as angiotensin
converting enzyme inhibitors (ACEIs) or angiotensin-II receptor
antagonists (ARBs) are used, as they have been found to delay the
clinical manifestations of the CKD [1,2,3,4]. Nevertheless, even
under treatment with ACEIs or ARBs, patients progressively lose
proper renal function. For these reasons understanding the
primary responses of the endothelium to each stages of the kidney
disease is of major importance for the design of efficient
therapeutic strategies.
The endothelium is the major site of control of vascular functions
[5]. Under physiological conditions the vascular endothelium regulates
processes that include vascular tone, vascular permeability to nutrients,
macromolecules and leukocytes recruitment (and thus inflammation),
platelet adhesion and aggregation, activation of the coagulation
cascadeandfibrinolysis[6,7,8,9,10,11].Endothelialdysfunction reflects
the combination of altered endothelial properties resulting to improper
preservation of organ function. Endothelial dysfunction might be
characterized by altered basement membrane synthesis, increased
vascular tone and permeability -which contributes to increased blood
pressure and atherogenesis- and loss of antithrombotic and profibri-
nolytic properties. Such alterations do not necessarily occur simulta-
neously and may differ according to the nature of the injury and the
intrinsic site-specific properties of endothelium.
CKD leads to altered properties and responses of the
endothelium [12,13,14]. However, the mechanisms by which
increased uremia might influence endothelial cells, and especially
the early responses of endothelial cells to the stimuli present in the
serum of patients with CKD, are still not well understood.
Systemic exposure of the vasculature to uremic toxins may lead to
endothelial activation [15] and to features associated with systemic
inflammation like hypertension and atherosclerosis. Hemodialysis
(HD) or nephrectomy are generally used as approaches for the
treatment of the sort-term effects of renal disease [16], nevertheless
patients under long term HD treatment do not have reduced risk
of vascular disease [17,18,19,20].
The present study was designed to investigate the short-term in
vitro effect of serum from patients with CKD on endothelial cells
and the relative effect of HD on endothelial cell activation and
function. We focused on the early responses of the endothelial cells
to the uremic toxins, before the inflammatory activation of the
endothelial cells (expression of adhesion molecules, secretion of
chemokines) is established. For this purpose sera from patients
either before or after the HD procedure were collected and their
relative effect on the activation of human umbilical vein
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enabled us to clearly use the best internal controls available since
the sera from the same patients were used. Our results clearly
demonstrate that the initial response of endothelial cells to uremic
toxins involves a rearrangement of the local micro-environment
and extracellular matrix, a response that was up to date not
appreciated.
Materials and Methods
Serum samples from CRF patients
Ten adult (men) patients on chronic maintenance HD, middle-
aged 4565 years old, who were clinically stable and free of active
infection, autoimmune diseases or other traditional factors
implicated to endothelial dysfunction (diabetes mellitus, hyperten-
sion, hyperlipidemia, smoking) and had no signs or symptoms of
cardiovascular disease, participated in the study. None of the
patients received antihypertensive drugs, immunosuppressive
treatment, lipid-lowering agents, non-steroidal anti-inflammatory
drugs or antioxidants such as vitamin E, C or allopurinol in the
preceding 4 weeks. End stage kidney disease was attributed to
glomerulonephritis in 3 cases, interstitial nephritis in 2 and
polycystic kidney disease in 3 and was undetermined in 2 cases.
The patients were routinely haemodialyzed three times weekly for
4.0 h with DCEA polysulfone membranes - surface 1.7 mm
2,
bicarbonate dialysate and low molecular weight heparin-enox-
aparin as anticoagulation. The dialysate was endotoxin-free
(Coatest Kabi Vitrum). Dialysis prescription was guided by the
goal of achieving a value of Kt/V$1.3. They were on
erythropoietin therapy and the mean dosage was 90.5 (range
30.2–162) U/kg body weight/week. Body mass index (BMI) was
calculated by dividing the weight in kilograms by the square of the
height in meters.
For this study, we obtained ethics approval from the ethics
committee of University of Patras.
Endothelial cell culture
Primary human umbilical vein endothelial cells (HUVEC) were
isolated from umbilical cord vein by collagenase digestion as
previously described [21] and used at passages 2–4. The cells were
grown as monolayers in M199 medium supplemented with 15%
fetal bovine serum (FBS), 150 mg/ml endothelial cell growth
supplement, 5 U/ml heparin sodium, 100 U/ml penicillin-strep-
tomycin and 50 mg/ml gentamycin. Cultures were maintained at
37uC, 5% CO2 and 100% humidity.
Migration assay
Migration assays were performed as previously described [22] in
24-well microchemotaxis chambers (Costar, Avon, France), using
uncoated polycarbonate membranes with 8 mm pores. Briefly,
HUVEC were harvested and resuspended at a concentration of
10
5 cells/0.1 ml in medium containing 0.25% BSA. The bottom
chamber was filled with 0.6 ml of medium containing 0.25% BSA
and pre- or post-HD serum at dilutions ranging from 5% to 20%
v/v. The upper chamber was loaded with 10
5 cells and incubated
for 4 h at 37uC. After completion of the incubation, the filters were
fixed with saline-buffered formalin and stained with 0.33%
toluidine blue solution. The cells that migrated through the filter
were quantified by counting the entire area of each filter, using a
grid and an Optech microscope at a 206magnification.
Cell proliferation assay
Cell number was assessed using the 3-[4,5-dimethylthiazol-2-
yl]-2,5- dimethyltetrazolium bromide (MTT) assay [23]. HUVEC
were seeded at 5610
4 cells/well in 24-well tissue culture plates in
the corresponding culture medium. Cells were incubated in the
absence of serum for 4 h. Pre- or post- HD serum was added to
the medium of the cells at dilutions ranging from 5% to 20% v/v
and the number of cells was measured after 48 h. MTT stock
(5 mg/ml in PBS) at a volume equal to 1/10 of the medium was
added and plates were incubated at 37uC for 2 h. The medium
was then removed, the cells were washed with PBS pH 7.4 and
100 ml acidified isopropanol (0.33 ml HCl in 100 ml isopropanol)
was added to all wells and agitated thoroughly to solubilize the
dark blue formazan crystals. The solution was transferred to a 96-
well plate and immediately read on a microplate reader (Biorad) at
a wavelength of 490 nm.
Cell number was also determined by crystal violet assay:
Adherent cells were fixed with methanol and stained with 0.5%
crystal violet in 20% methanol for 20 min. After gentle rinsing
with water, the retained dye was extracted with 30% acetic acid
and the absorbance was measured at 590 nm.
Annexin-V Binding Staining
The Annexin V-FITC Detection Kit I (PharMingen, San
Diego, CA) was used according to the manufacturer’s instructions.
Cells were serum-starved for 4 h and pre- or post-HD serum was
added to the medium of the cells at 20% v/v dilution. Cells were
collected after 12 or 24 h incubation. Samples were analyzed in a
FACScan flow cytometer (Becton Dickinson). For each sample,
10,000 ungated events were acquired.
In vitro endothelial cell wound healing assay
HUVEC were grown in 6-well plates as confluent monolayers.
The monolayers were incubated in the absence of serum for 4 h
and wounded in a line across the well with a 200-ml standard
pipette tip. Cells were washed twice with serum-free media and
incubated with 20% v/v pre- or post-HD serum for 24 h. The
area of the initial wound was photographed using a charge-
coupled device camera connected to an inverted microscope
(Axiovert 35; Zeiss, Thornwood, NY). The wound healing effect
was calculated compared with the area of the initial wound.
Gelatin Zymography
The activity of MMP-2 and MMP-9 was examined by
zymography as previously described [24]. Endothelial cells were
cultured in 6-well plates as confluent monolayer. HUVEC were
serum-starved for 4 h and then incubated with culture medium
supplemented with 20% pre- or post- HD serum. 4 h later the
medium was replaced by minimal medium. 8 or 20 h later the
media were collected, centrifuged, and aliquots of the supernatants
were loaded with a non-reducing sample buffer onto a 10%
sodium dodecyl sulfate (SDS)-polyacrylamide gel containing
1 mg/mL gelatin and electrophoresed. Gels were washed twice
with 2.5% Triton X-100 solution for 30 min and once with
10 mM Tris-HCl buffer (pH 8.0) for 30 min. Gels were further
incubated in 50 mM Tris-HCl (pH 8.0) containing 0.5 mM CaCl2
and 0.1 mM ZnCl2 at 37uC for 24 h. The gels were stained with
1% Coomassie Blue R-250 in 10% methanol and 5% acetic acid
and subsequently destained with 10% methanol and 5% acetic
acid. The relative amounts of MMP-9 and MMP-2 were
quantified by NIH Image Analysis software and normalized to
the total number of cells of each well (using Crystal violet method).
Immunoblot analysis
Endothelial cells were cultured in 6-well plates as confluent
monolayer. HUVEC were serum-starved for 4 h and then
Uremic Toxins in Endothelial Dysfunction
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post- HD serum. 4 h later the medium was replaced by minimal
medium. 8 or 20 h later the media were collected, centrifuged, and
aliquots of the supernatants were analyzed by SDS-PAGE and
proteins were blotted onto PVDF membranes (Millipore, Bedford,
MA). Blocking was performed in a 5% fat-free dry milk in 0.2%
Tween-20 in PBS and membranes were further incubated with
primary antibodies for 1 h (1:2000 dilution in TBS containing
0.1% Tween 20 (TBS-T) and 1% BSA), washed with 0.1%
Tween- 20 in PBS, and then incubated with anti-mouse
peroxidase-conjugated secondary antibody (1:2000 in TBS
containing 0.1% Tween 20 (TBS-T) and 3% fat free dry milk).
Visualization of immunoreactive proteins was performed with
enhanced chemiluminescence reagents (ECL kit; Amersham
Pharmacia Biotech). The normalization was based on the number
of cells of each well that was estimated using Crystal violet method.
RNA isolation and reverse transcriptase-polymerase chain
reaction analysis of MMP-2,-9 and TIMP-1, -2 mRNA
Total RNA was isolated from HUVEC cultured with 20% pre-
or post-HD serum for 6, 12 or 24 h using NucleospinH RNA II
(Macherey-Nagel) according to manufacturer’s instructions. Re-
verse transcriptase-PCRs were performed using the Access
Reverse Transcriptase-PCR system (Promega). The sequences of
the primers used in our studies are the following: GAPDH: 59-
TCT AGA CGG CAG GTC AGG TCC ACC-39 and 59-CCA
CCC ATG GCA AAT TCC ATG GCA- 39, MMP-2: 59-ACA
GTC CGC CAA ATG AAC C- 39 and 59-CCT GGG CAA CAA
ATA TGA G- 39, MMP-9: 59-GCC TTG GAA GAT GAA
TGG AA - 39 and 59- CAT CGT CAT CCA GTT TGG TG- 39,
TIMP-1: 59-TGC AGT TTT CCA GCA ATG AG - 39 and 59-
CTG TTG TTG CTG TGG CTG AT - 39, TIMP-2: 59-TTT
GAG TTG CTT GCA GGA TG - 39 and 59-ATT TGA CCC
AGA GTG GAA CG -39, COLLAGEN IV: 59-TTT CCA GGG
TAG CCA GAT GCT C - 39 and 59-GGG GTT ACA AGG
TGT CAT TGG G - 39, ELASTIN: 59-CCA TAC TTG GCT
GCC TTA GC - 39 and 59-CAC TGG GGT ATC CCA TCA
AG - 39.
Statistical analysis
Comparison of mean values among groups was done using
ANOVA and the unpaired Student t-test. Homogeneity of
variance was tested by Levene’s test. Each experiment included
at least triplicate measurements for each condition tested. All
results are expressed as the mean 6 SD of at least three
independent experiments. Values of p less than 0.05 were taken to
be significant (*p,0.05, **p,0.01, ***p,0.001).
Results
Uremic toxins present in the serum of patients with CKD
alter endothelial cell properties in vitro
Although CKD is positively associated with dysfunction of the
endothelium, the effect of the uremic toxins of patients on the
immediate responses of endothelial cells is not clearly demonstrat-
ed. To study the above mentioned effect, we isolated sera from
patients with CKD right before or after HD, an approach that was
not followed or appreciated in previous studies. At first we
investigated the role of uremic toxins in the sera of our patients on
the proliferation of endothelial cells. We incubated HUVEC with
three different concentrations of sera. As shown in Figure 1A,
incubation of HUVEC with increased concentrations of pre-HD
serum resulted in reduced proliferation of endothelial cells
compared to the relative concentrations of post-HD serum.
Increased concentrations of serum resulted in increased prolifer-
ation in both pre- and post-HD sera, nevertheless in all the
concentrations tested in our experiments the effect on proliferation
was enhanced in the samples stimulated with post-HD serum. The
stimulatory effect of the uremic toxins-free serum (post-HD serum)
on the proliferation of HUVEC reached 30% compared to the
pre-HD serum, when a concentration of 20% was used in the
medium. These results indicate that the differential concentration
mainly of uremic toxins present in the serum of patients with CKD
before and after HD affects proliferation of primary endothelial
cells in vitro.
Basal apoptosis can be observed in cultured cells under normal
conditions. Furthermore, since post-HD serum is not believed to
be completely free of uremic toxins, we investigated the effect of
either pre- or post-HD serum on the apoptosis of HUVEC in vitro.
We used the concentration of 20% of serum in the cultured
medium where the effect on HUVEC proliferation was more
pronounced. As shown in Figure 1B, incubation of endothelial
cells with either pre- or post-HD sera leads to a time dependent
increase in the percentage of apoptotic cells. This effect is more
pronounced when cells are cultured with pre- HD serum and
reaches an 80% increase in the number of apoptotic cells
compared to cells cultures with post-HD sera after 72 hours.
Nevertheless, the percentage of apoptotic cells in culture even
under these conditions cannot be the soul reason for the decreased
total number in our proliferation assays (Figure 1A), arguing for a
combined effect of uremic-toxins on both the proliferation and cell
survival of endothelial cells.
It is known that systemic inflammation affects the migration of
endothelial cells, inhibiting the healing processes in vivo [25]. To
study the effect of uremic toxins on migration, we incubated
HUVEC with increasing concentrations of either pre-HD or post-
HD serum. As shown in Figure 1C, pre-HD serum has a realtivelly
small positive effect on the migration of endothelial cells in the
different concentrations used. On the contrary, when post-HD
serum was used, a dose-dependent induction on the migration of
endothelial cells was observed that reached almost 70% induction
at serum concentration of 20%.
The combination of endothelial cells proliferation/survival and
migration in vivo might have an impact in wound healing processes.
The effect of the concentration of uremic toxins before and after
the HD in the healing responses of endothelial cells in vitro has not
been so far addressed. To investigate this we used the widely used
scratch assay. Wound repair was assessed 24 h after incubation
with 20% pre- or post-HD serum. As shown in Figure 1D,
endothelial wound repair in monolayers exposed to pre-HD serum
was significantly lower than in cells exposed to post-HD serum.
Uremic toxins present in the sera of patients with CKD
promote the expression and activity of ECM-degrading
proteinases
So far our results indicate that the uremic toxins alter the
biological activities of endothelial cells in vitro, and are in
accordance with previously published data [26,27,28,29,30].
Nevertheless, previous studies have been focused on the response
of endothelial cell (in vitro) after long term stimulation with
inflammatory stimuli or of the endothelium (in vivo) under
conditions of systemic inflammation. We decided to focus on the
early responses of endothelial cells upon stimulation with uremic
toxins sera. At first we tested if the serum from the same patients
before or after the HD could affect the deposition of extracellular
matrix. We stimulated HUVEC with the above-mentioned sera
and assessed for the activation of metalloproteinases (MMPs)
either at the protein level by zymography on the medium of the
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the pre-HD serum induces a dose dependent increase in both
MMP-2 and MMP-9 protein levels in the medium of HUVEC as
compared to the relevant samples where post-HD serum was used.
Since the difference was more pronounced when 20% of either
pre- or post-HD serum was added to the culture medium, we
performed all following experiments using this serum concentra-
tion. As shown in Figure 2B, incubation of HUVEC with pre-HD
serum led to increased MMP-9 activity in the cell supernatant after
12 and 24 hours, while it also increases MMP-2 protein levels after
24 hours as compared to the effect of the post-HD serum.
Furthermore incubation of HUVEC with pre- or post- HD serum
at the concentration of 20% induces MMP-2 and MMP-9
expression levels in a statistically significant manner reaching a
maximum at 6 and 12 hours respectively (Figure 2C).
Since both in vitro and in vivo, activity of MMPs is counter-
balanced by the expression of naturally expressed inhibitors (tissue
inhibitors of metalloproteinases, TIMPs), we assessed the expres-
sion levels of TIMP-1 and TIMP-2 protein levels on supernatants
from HUVEC that were stimulated with sera at the concentration
of 20%. As shown in Figure 3A, we observed a statistically
significant increase of TIMP-1 and TIMP-2 protein levels when
HUVEC were incubated with post-HD serum, compared to pre-
HD serum. This increased accumulation of TIMP-1 and -2
proteins in the medium of cells cultured with uremic-free sera can
be attributed to increased expression of the relative genes, as
shown in Figure 3B.
Uremic toxins present in the sera of patients with CKD
inhibit the expression of extracellular matrix proteins
To investigate the effect of uremic toxins in the sera from
patients with CKD on the expression of extracellular matrix
components by endothelial cells we analyzed the expression levels
of collagen IV and elastin. As shown in Figure 4, incubation of
endothelial cells with either pre- or post-HD sera induces the
expression of both collagen IV and elastin. This increase is more
pronounced when endothelial cells are incubated with the post-
HD serum. These data suggest that uremic toxins could inhibit the
Figure 1. Effect of pre- or post-HD serum on proliferation, apoptosis, migration and wound healing activities of HUVEC. (A): HUVEC
were incubated in medium supplemented with 5%, 10%, 20% pre- or post-HD serum and 48 h later their number was estimated by crystal violet. (B):
HUVEC were incubated in medium supplemented with 20% pre- or post-HD serum and 48 or 72 h later the number of apoptotic cells was measured
by FACS. (C): HUVEC were incubated in microchemotaxis chambers in culture medium supplemented with 5%, 10%, 20% pre- or post-HD serum and
4 h later the number of cells that migrated through the filter was quantified. (D) Endothelial monolayers were scratched, incubated in culture
medium supplemented with 20% pre- or post-HD serum and 24 h later representative images of the plates were taken. Data are expressed as mean
6 SEM of three independent experiments.
*,
** and
*** represent p,0.05, p,0.01 and p,0.001 respectively.
doi:10.1371/journal.pone.0030975.g001
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PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e30975Figure 3. Effect of pre- or post-HD serum on the expression of TIMP-1 and TIMP-2. (A): HUVEC were incubated in culture medium
supplemented with 20% pre- or post- HD serum. 4 h later the medium was replaced by minimal medium and 8 h or 20 h later the supernatants were
analyzed for TIMP-1 and TIMP-2 proteins by SDS-PAGE. (B): HUVEC were incubated with culture medium supplemented with 20% pre- or post- HD
serum. 6, 12, or 24 h later total RNA was extracted from the cells, RT-PCR reactions were performed using specific primers for TIMP-1, TIMP-2 or
GAPDH mRNAs, the PCR products were analyzed in agarose gels and quantified. Data are expressed as mean 6 SEM of three independent
experiments.
* and
** represent p,0.05 and p,0.01 respectively.
doi:10.1371/journal.pone.0030975.g003
Figure 2. Effect of pre- or post-HD serum on MMP-2, -9 expression. (A): HUVEC were incubated in medium supplemented with 5%, 10%, 20%
pre- or post- HD serum. 4 h later the medium was replaced by minimal medium and 20 h later the supernatants were analyzed for MMP-2 and MMP-
9 activity by zymography. (B): HUVEC were incubated with culture medium supplemented with 20% pre- or post- HD serum. 4 h later the medium
was replaced by minimal medium and 8 or 20 h later the supernatants were analyzed for MMP-2 and MMP-9 activity by zymography. (C): HUVEC were
incubated in culture medium supplemented with 20% pre- or post- HD serum. 6, 12, or 24 h later total RNA was extracted from the cells, RT-PCR
reactions were performed using specific primers for MMP-2, MMP-9 or GAPDH mRNAs, the PCR products were analyzed in agarose gels and
quantified. Data are expressed as mean 6 SEM of three independent experiments..
*,
** and
*** represent p,0.05, p,0.01 and p,0.001 respectively.
doi:10.1371/journal.pone.0030975.g002
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or local endothelial loss due to apoptosis.
Discussion
Uremic toxins contribute to endothelial dysfunction in CKD. In
renal failure, endothelial dysfunction and cardiovascular compli-
cations are closely linked [14,31–35]. Endothelial cell damage
correlates with thrombosis, hypertension and may be also
responsible for accelerated atherosclerosis in patients with CKD.
Traditional risk factors cannot explain the high incidence of
cardiovascular disease in patients with CKD therefore several
studies focus on other parameters such as endothelial dysfunction
or insulin resistance. In this paper, we focused on the mechanism
of endothelial dysfunction induced by uremic toxins, including the
remodelling of the extracellular matrix.
Our results demonstrate that uremic toxins modulate primary
responses of endothelial cells that correlate with the function of
endothelium in vivo. Endothelial loss, due to apoptosis leads to
vascular complications like thrombosis, increased inflammatory
infiltration to the intimal area of the arteries and impaired NO
production that lead to hypertension and atherosclerosis. Our
results demonstrate that uremic toxins induce apoptosis of
endothelial cells in vitro. This result is in line with previous reports
that link increased endothelial cell apoptosis and renal failure, an
effect that was mainly attributed to increased levels of AGEs
[34,36]. In vivo loss of the endothelial monolayer leads to the
formation of a thrombus but it might also be compensated by the
increased proliferation of endothelial cells neighboring the
damaged area or from direct recruitment of endothelial cell
precursors from the bone marrow or circulation [37]. Our results
indicate that in parallel to the increased apoptosis that is observed
in endothelial cells when they are incubated with media containing
uremic toxins, a decreased proliferation and migration capacity of
the endothelial cells is observed. These results might also explain
the thrombophilia that is observed in patients with renal failure
that often leads to vascular clotting, heart attacks and strokes. The
fact that increased apoptosis, reduced proliferation and inhibition
of migration were dependent on the concentration of the serum as
well as the fact these effects were reversed by HD, indicate that the
primary response of endothelial cells to ingredients of the sera in
patients with CKD is to the uremic toxins. This result is of
particular interest since in a previous study low levels of AGEs
were not linked to a better survival rate in HD patients [38]. Our
results indicate thought that HD significantly improves endothelial
biological functions in vitro indicating that the primary endothelial
damage is related most probably to uremic toxins.
Several studies indicated the role of disturbed extracellular
matrix metabolism in defective myocardial and vascular remod-
elling [39–52]. Therefore MMPs as well as their tissue inhibitors
have been proposed as a group of factors that add to the
pathogenesis of atherosclerosis. Animal models and in vitro
investigations have shown their multifaceted actions, varying from
protective and anti-atherogenic in the case of TIMP-2, through
neutral of TIMP-1 or ambiguous of MMP-9, to pro-atherogenic of
MMP-2 [52–57]. Moreover, gelatinases A and B (MMP-2 and
MMP-9) constitute risk factors for myocardial infarction [58]
whereas their tissue inhibitors TIMPs have an impact on
postmyocardial infarction remodelling [59,60] and correlate
positively with left ventricular mass and wall thickness [61]. The
role of MMPs in CKD has been studied extensively [62–65], and
especially the impact on ischemic acute renal injury and scarring
in the course of glomerulopathies [66–68].
Our data demonstrate that uremic toxins modulate the
expression of MMP production by endothelial cells in vitro as well
as their enzymatic activity. Interestingly, our data clearly
demonstrate an opposite effect of uremic toxins on the production
of MMPs and TIMPs. When the protein levels were evaluated a
clear reduction in the production of TIMP-1 and -2 was observed
in endothelial cells that were cultured with pre-HD serum.
Relative expression levels of TIMP RNA supported these results.
Figure 4. Effect of pre- or post-HD serum on the expression of collagen-IV and elastin. HUVEC were incubated with culture medium
supplemented with 20% pre- or post- HD serum. 6, 12, or 24 h later total RNA was extracted from the cells, RT-PCR reactions were performed using
specific primers for Collagen IV, Elastin or GAPDH mRNAs, the PCR products were analyzed in agarose gels and quantified. Data are expressed as
mean 6 SEM of three independent experiments.
*,
** and
*** represent p,0.05, p,0.01 and p,0.001 respectively.
doi:10.1371/journal.pone.0030975.g004
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when endothelial cells were cultured with post-HD serum were
followed by a moderate increased production of TIMPs at
prolonged periods of incubation of endothelial cells with pre-HD
serum. This response of the cells to uremic sera can only be
explained by a time-dependent and well-orchestrated response of
endothelial cells in ‘‘danger signals’’ in vivo [69–72]. The original
response of endothelial cells to uremic toxins leads to the activation
of MMPs without affecting the initial levels of TIMPs. Further
exposure of the endothelium might initiate the activation of
inhibitory pathways that aim the resolution of the inflammation
produced by the uremic toxins. In the absence of obvious uremia
(like in the case of post-HD serum) the relative production of
MMPs versus TIMPs seems to be more balanced which most
probably reflects the response of a functional endothelium in vivo.
Such an endothelial response to uremic toxins in vivo might lead to
degradation of the extracellular matrix and the basal membrane of
the endothelial cells, leading to increased endothelial loss due to
anoikis in vivo. One could speculate that the expression of MMPs
might potentiate the ability of the endothelial cells to modulate the
extracellular matrix locally and induce wound healing. Though,
this is most probably not the case since our experiments clearly
demonstrate a decreased ability of endothelial cells to migrate and
cover damaged regions in vitro. The increased MMP production
seems to correlate more with the increased thrombotic incidence
and atherosclerosis observed in patients with kidney disease.
Increased MMP activity correlates with atherosclerosis develop-
ment and plaque rupture. Plaque vulnerability especially is linked
to intimal thickening, loss of the collagen fibrous cap surrounding
mostly necrotic areas of atherosclerotic lesions, or increased
angiogenesis and hemorrhage within the atherosclerotic lesions.
Our results suggest that uremic toxins, by modulating the
expression and activity of MMPs might be major regulators of
the thrombogenic incidents observed in patients with CKD.
Our results demonstrate that endothelial cells contribute at the
early response to uremic toxins to the overall systemic inflamma-
tion observed in patients with CKD. This response resembles the
procedure of the activation of the endothelium during atheroscle-
rosis. During the early stages of atherosclerosis progression
endothelial cells express adhesion molecules (e.g. VCAM-1,
ICAM-1, E-selectin) as well as chemokines (e.g. MCP-1, MCP-3,
Fractalkine) [25,69,73,74] upon activation of the nuclear factor-
kappa B [75]. This response leads to the recruitment of immune
cells (namely monocytes) into the intima of the large arteries. At
latter stages the disease does not depend on the endothelial
response but mainly to the cells of the immune system either
resolve the initial inflammation or activate an adaptive immune
response [76–78]. We would like to propose a similar process
during the development and establishment of CKD At the early
stages the accumulation of uremic toxins in the plasma of patients
could lead to altered functions of the endothelium, reorganization
of the extracellular matrix of the large arteries and an
inflammatory response. At latter stages, the presence of uremic
toxins might have no effect on the activation of specific molecular
response in endothelial cells, though it could contribute to
increased apoptosis and reduced wound healing. The practical
significance of this hypothesis, and the stage where the progression
of the disease is still endothelial-dependent definitively deserves
further investigation.
The advantage of this study relies on the fact that we used pre-
HD and post-HD sera from the same patients. To our
understanding our approach provided the best internal controls
to study the direct effect of uremic toxins present in patients with
CKD on endothelial cells. This approach prevented us from using
sera from healthy patients since HD could not be applied.
Nevertheless this was not the aim of this study that aimed on the
net effect or uremic toxins on endothelial cells and not the overall
effect of sera from patients with CKD compared to normal sera on
endothelial cells (an approach that was used extensively in the
past). Our results demonstrate that uremic toxins contribute to a
great extend to deregulation of endothelial cells, most probably at
the early stages of the development of kidney disease. Further
studies are ongoing regarding the clinical evaluation and
significance of our results.
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